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cantly increased during last five years. There is a need for prevention, treatment
and disease management programs to lower the medical and socioeconomic bur-
den of this disease.
Urinary/Kidney Disorders – Research on Methods
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A SIMULATION MODEL OF THE EFFECTS OF TREATMENTS FOR SECONDARY
HYPERPARATHYROIDISM ON MORTALITY
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OBJECTIVES: Secondary hyperparathyroidism (SHPT) is a common condition in
dialysis, characterized by high levels of associated laboratory parameters (LABS):
parathyroid hormone (PTH), serum calcium (Ca) and phosphorous (P). Cinacalcet
can be effective in controlling LABS in SHPT. Objective of this study was to develop
a model to simulate the impact of cinacalcet versus standard treatment (ST) on
patient mortality.METHODS: The model used the latest data on cinacalcet efficacy
in lowering LABS from the OPTIMA and ADVANCE interventional trials together
with the estimated relationship between LABS and mortality from the ARO obser-
vational study on 7970 haemodialysis patients treated in European Fresenius Med-
ical Care facilities. Patient-level data from the 6-month OPTIMA and 12-month
ADVANCE studies were pooled and regression models were fitted with post-treat-
ment values as the response to derive functions predicting 12-month LABS values
from their starting values, patient characteristics and treatment. After 12 months
LABS were assumed constant except for PTH in ST (assumption of a 170 pg/ml per
year increase). Mortality was calculated as that of the dialysis population multi-
plied by relative risks as function of LABS. The model was compared with a Block
observational study analyzing mortality rates (26-month follow-up) in 19,186 hae-
modialysis patients treated at the DaVita dialysis provider in the US. The simula-
tion was run with patient characteristics replicating the DaVita cohort and base
mortality rates from the US Renal Data System. RESULTS: The simulated death
rates (year 1: cinacalcet 18.4%, ST 22.6%, RR0.81; year 2: cinacalcet 32.9%, ST
40.8%, RR0.81) were close to the observed data in the Block study (year 1: cinacal-
cet 15%, ST 20%, RR0.75; year 2: cinacalcet 30%, ST 37%, RR0.81). CONCLUSIONS:
The model showed effects of cinacalcet on mortality similar to those observed in
the DaVita US cohort. This mortality model will be a useful tool for future health-
economic analyses of cinacalcet in SHPT.
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OBJECTIVES: To explore the known-group validity of the Spanish version of the
self-administered OABq-SF questionnaire, which feasibility, reliability and con-
struct and criterion validities have previously been shown. METHODS: The cultur-
ally adapted Spanish version of OABq-SF was administered on two occasions 3
months apart to a set of patients of both genders, 18 years, diagnosed of OAB
according with standard criteria and a score  8 in OAB-V8 scale and able to un-
derstand and filling-in PRO instruments written in Spanish. Patients were recruited
consecutively at clinics of Urology all over the country. Known-groups validity was
explored using the sample of patients classified in quartiles according to their
responses in the OAB-V8 scale at the baseline visit. Patients were compared in the
OABq-SF: symptom bother and HRQoL. For known-group testing purposes, base-
line scores in the OABq-SF questionnaire were used. ANOVA, descriptive statistics
and Pearson=s r coefficients were computed for data analysis. RESULTS: The study
enrolled a total of 246 OAB patients (mean age 57.7 years; 76% women, 99% Cauca-
sian, 37% active workers and 36% primary schooling) at 18 urological. OAB-V8
scores significantly correlated (Pearson=s r coefficient) with OABq-SF domains;
0.790 and0.659 for symptom bother and HRQoL domains, respectively (p0.001
in both cases). Mean (95% CI) of the OABq-SF domain scores were significantly
different between OAB-V8 quartile groups; 39.1 (36.0-42.3), 48.0 (44.5-51.5), 56.7
(53.6-59.8) and 74.6 (71.4-77.7) points for 1st, 2nd, 3rd and 4th quartile groups,
respectively (F10.5, p0.001) in symptom bother domain, and 66.8 (6.1-70.5), 60.5
(56.4-64.6), 53.5 (49.9-57.2) and 37.8 (34.0-41.6) points average score, respectively
(F32.9, p0.001) in HRQoL domain. CONCLUSIONS: The Spanish version of the
OABq-SF instrument provided evidence of known-group validity according with
patient-rated severity of symptom bother in the OAB-V8 scale.
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IMPROVING PATIENT SAFETY IN THE UK AND ENGAGING PATIENTS IN
RESEARCH: A NEW MODEL FOR THE NHS?
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OBJECTIVES:The purpose of this study was to determine awareness of and interest
in research amongst members of a web-based medicines monitoring service and to
solicit opinions on whether this service should be offered by the NHS. METHODS:
In May 2011, we surveyed 150 uk.MediGuard.org members: 50 in England, Scotland,
and Wales. uk.MediGuard.org is a free medicines monitoring service covering over
2.5 million patients, including 100,000 in the UK. RESULTS: Ninety-one percent of
respondents rate the MediGuard service as good or excellent and 99% are unaware
of similar services in the UK. When asked whether the National Health Service
(NHS) should introduce MediGuard to all patients, 93% responded yes and 89% said
that offering the service would positively impact their impression of the NHS (43%
significantly, 46% somewhat positive impact). While only 12% have ever enrolled in
a trial, 71% were at least somewhat interested in participating in the next 12
months (23% extremely, 17% very, 31% somewhat interested). The primary reason
why patients have not enrolled in a trial is lack of awareness (68%); only 16%
mentioned lack of participation due to concerns about an experimental drug.
CONCLUSIONS: Survey results show that engagement in a medicines monitoring
service is an effective method for improving outcomes and increasing awareness of
clinical trials; pilot studies are now underway. Historically, the NHS has been slow
to pursue public-private partnerships, however, NHS efforts to stimulate on-line
patient engagement have not been a huge success (e.g., HealthSpace enrolled 3,000
in the first year at a cost of £8 million). Recognizing that all UK countries have
initiatives to increase participation in research, perhaps it is time for the NHS to
reconsider the role of partnerships to leverage the explosion of web-based appli-
cations as a method for stimulating research.
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OBJECTIVES: This study aimed to assess the opinion of the French population on
the publication of a list of 77 medicines under regulatory monitoring (surveillance
list, published following market withdrawal of diet adjuvant benfluorex) in France
and more specifically evaluate its impact on consumer behaviour. METHODS: A
total of 928 French individuals answered a phone questionnaire consisting of 37
closed questions and 3 open-ended questions. Respondents were aged 30 and over
since this age group is expected to be more prone to diseases and chronic pathol-
ogies. The study, carried out in March 2011, was compliant with the French Na-
tional INSEE quota methodology. RESULTS: Around 7% of the sample population
declared using at least one of the products included in the French surveillance list.
Of these, over one in three persons indicated their intention to stop or suspend
their treatment in reaction to their medicine’s regulatory surveillance while one in
three persons did not intend to change their treatment intake. Meanwhile, in the
larger study sample, nearly one in six persons declared considering reducing their
medicine purchasing patterns as a result of the surveillance list publication, a
figure in line with studies conducted prior to the publication of the list. Finally,
treatment compliance was reported at 85.8% pre-surveillance list publication and
83.5% post-surveillance list publication. CONCLUSIONS: French consumer confi-
dence in pharmaceuticals in general is mostly unaffected by the new surveillance
list. However, consumer behaviour is strongly affected by product inclusion onto
the surveillance list, especially for those patients treated with at least one listed
treatment. Furthermore, consumer confidence in healthcare regulators, off-label
prescribing and pharmaceutical companies was negatively affected by the benfluo-
rex case. Prescribers will have a pivotal role in maintaining overall confidence
through patient communication and information.
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OBJECTIVES:We use discrete choice experiment to analyze which attributes (qual-
ity, access, and price) influence patients’ choice between health care providers. We
also estimate the willingness-to-pay of respondents for the improvement of health
care characteristics. METHODS: Data was collected via household survey con-
ducted by face-to-face interviews in Hungary, 2010. Respondents were selected
based on multistage random probability method. In total, 1037 respondents filled in
the questionnaire. In DCE, eight choice set for the physician and eight for hospital
services were presented to the respondents in the form of alternative and basic
profiles that contained combinations of attributes of health care services. Attri-
butes and attribute levels were developed on the basis of literature review. For the
analysis binary probit regression with random effects was used including attribute
differences as well as interactions of attribute differences and socio-economic
characteristic as independent variables. Marginal rates of substitution (MRS) were
calculated to indicate the willingness-to-pay of the respondent for the improve-
ments in the attribute levels. RESULTS: The response rate of the survey was 67%.
Significant negative regression coefficients (p0.1) of the interactions between
price and social economic characteristics show that respondents from a village or
the capital, with low education and bad health status were more sensitive to
changes in the price attribute when choosing between health care providers. MRSs
show that respondents are willing to pay the most for the good skills and reputa-
tion of the physician and the attitude of the personnel, followed by modern equip-
ments and maintenance of the office/hospital. Access attributes (travelling and
waiting time in front of the office) were less important. CONCLUSIONS: DCE
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method is useful to reveal patient preferences, and might support the development
of evidence-based and sustainable health policy on patient charges in Central-and
Eastern European countries.
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OBJECTIVES: To determine the factors associated with paediatric inappropriate
use (IU) of the accident and emergency department (A&E) METHODS: An observa-
tional prospective survey was performed. All the patients attending A&E in 12
Belgian hospitals during 2 weeks in 2010 were included. The use of A&E was con-
sidered appropriate if, at least, one of the following criteria was met: child referred
by a doctor or the police, brought by ambulance, need for a short stay[i], need for
technical examination or orthopaedic treatment, in patient admission, death.
RESULTS: The median age of the 3220 children included was 3.3 years old (0-15.9);
39.3% of the visits were not appropriate according to the definition above. Five
determinants were included in a multivariate analyze: age, having a family doctor,
night or week-end use of A&E, parents’ perception of severity for child’s illness and
insurance status. Two factors were associated with a decrease of IU: parents’ per-
ception of high severity for child’s illness (Adjusted OR 0.6; 95% IC 0.4-0.8) and
having a family doctor (Adjusted OR 0.6; 95% IC 0.4-0.9). Two other factors were
associated with an increase of IU: children age less than 2 years (Adjusted OR 1.8;
95% IC 1.5-2.2) and night or week-end use of A&E (Adjusted OR 1.4; 95% IC 1.1-1.7).
After adjustment, the insurance status has no more impact on the appropriateness
of A&E use.CONCLUSIONS: In a country like Belgium, where it is not compulsory to
be registered with a family doctor, the risk of an IU is mainly due to the failure of
outpatient care for children2 years and the use of A&E during night or weekend.
Parents’ perception of high severity for child’s health status and having a family
doctor were associated with the appropriateness of A&E use.
Health Care Use & Policy Studies – Diagnosis Related Group
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ANALYSIS OF LINKED MEDICAL CLAIMS DATA FOR PREINVESTIGATION IN
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OBJECTIVES: Medical databases that contain comprehensive claims data linked to
individual patients can be an important source for the parameterization of deci-
sion-analytic models. Moreover, they are useful for preliminary studies that aim to
identify promising research questions and crucial health problems. The goal of this
research was on the one hand to analyze health care utilization of children and
adolescents using claims data of Austria’s social health insurances and on the
other hand to gain insight into the general usefulness of the data for further mod-
eling studies. METHODS: The database contains all claims data from the insured
population during two years (2006 and 2007). We selected patients who were alive
and under 20 years old on 1 January 2007. These represented the base population
for the analyses. As the database contains no medical diagnoses in ambulatory care
we used the drug prescription data and statistically identified links between ATC
codes on level 3 and ICD-9 groups (Weisser et al., 26th PCSI Conference, Munich,
2010). RESULTS: The basic population consisted of 1, 885, 037 individuals. Antiin-
fectives for system use (ATC code “J”) were by far the most prescribed drug group
with 1,231,496 prescriptions. Based on medical prescriptions 646 790 / 685,946 per-
sons were linked to acute respiratory infections in 2006 / 2007. As expected the
provider types with most consultations were general practitioners, dentists and
pediatrists. CONCLUSIONS: The first step for preinvestigation – the identification
of relevant diseases and related subpopulations – requires a linkage of reimburse-
ment claims to diagnoses (in this case via drug prescriptions). Afterwards it is
possible to analyze the health care utilization and to identify further medical
events of the subpopulation as long as all the data is linked to individuals. Our
results on child and adolescent health care utilization can point out further direc-
tions for future modeling studies.
Health Care Use & Policy Studies – Drug/Device/Diagnostic Use & Policy
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REGIONAL VARIABILITY IN THE GENERIC ANTIDEPRESSANT MARKET IN SPAIN
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OBJECTIVES: The Spanish antidepressant market is the 7th market in volume in
Spain, and represented 475 million Euros in 2010. As a measure to contain phar-
maceutical expenditure and promote rational drug use, the Spanish Autonomous
Regions (AR) have implemented, among other policies, prescription quality indica-
tors for generics (PQIG). The objective of this study was to analyze the generic
antidepressant market in those AR with and without PQIG and to assess whether
the AR with PQIG have higher generic sales than those without indicators.
METHODS: We identified the AR with PQIG, through their health services web
pages. We obtained the sales of branded and generic antidepressants (SSRIs, NS-
MRIs, MAOIs and other antidepressants) in volume (units) for each AR for the
period 2007-2010 – data obtained from IMS Health® Regional database. Sales were
adjusted per one million population – data obtained from National Statistics Insti-
tute. From these data, we estimated generic prescription and compared growth for
the period 2007-2010. RESULTS: Nine out of the 17 AR have PQIG (Andalusia, Bale-
aric Islands, Catalonia, Castilla-La Mancha, Castilla-León, Madrid, Basque Country,
La Rioja and Valencia). Generic prescription increased 8 points from 2007 to 2010,
both groups having similar growth (8 and 7 points in the PQIG and non-PQIG group,
respectively). In 2007, the mean generic prescription in the AR with PQIG was the
14%, whereas in the non-PQIG group was 10%. In 2010, it was 22% in the AR with
PQIG and 17% in the non-PQIG ones. Andalusia and Catalonia were the AR with the
highest percentage (38% and 28%, respectively) and Murcia and Country Basque
were the lowest (11% and 14%, respectively). CONCLUSIONS: The PQIG had an
overall positive impact in generic prescription, although other factors, such as PQIG
implementation approach may influence the real impact of indicators in sales.
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OBJECTIVES: Orphan drug legislations have been introduced to encourage the de-
velopment of orphan drugs. In the European Union (EU), orphan drugs are used for
the diagnosis, prevention or treatment of life-threatening or serious conditions
that affect  5 in 10,000 people. It is estimated that approximately 7000 rare dis-
eases exist. We assessed the characteristics and outcomes of the new drug devel-
opment for rare diseases in the EU. METHODS: Data on therapeutic indications for
the cohort of orphan drugs authorised in the EU were extracted from the European
Public Assessment Reports of the European Medicines Agency (EMA) and the Eu-
ropean Commission Register of medicinal products (up to June 2011). RESULTS:
Overall, 64 orphan drugs were authorised in the EU since 2000, corresponding to a
total of 77 indications. Median time from orphan designation to EMA authorisation
was 2.6 years (P25-P75: 1.5-4.5 years). Sixty percent of the total indications were for
the treatment of rare diseases that affect  1 in 10,000 people. By therapeutic area,
the percentage of indications with a marketing authorisation was heterogenous
(e.g., 45% for malignant neoplasms, 32% for blood and endocrine disorders, 6% for
cardiovascular diseases, 6% for neurological and mental conditions, or 3% for peri-
natal conditions, among others). CONCLUSIONS: Regulatory reform efforts have
contributed to the development of orphan drugs. Further research is needed to
explain whether unmet needs are being addressed among patients with rare dis-
eases.
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OBJECTIVES: Originally intended for drug utilization studies, ATC classification is
now increasingly used worldwide as a tool for controlling prices of pharmaceutical
products. This research looked at how select markets within Europe and Latin
America have incorporated ATC classification into their pricing policies to drive
down prices of similar drugs. METHODS: The research was conducted through
in-depth secondary analysis and primary research. National and regional level
payers from 10 countries within Europe and Latin America were interviewed using
structured discussion guides to explore the role of ATC classification in their re-
spective countries. RESULTS: ATC classification is used in varying degrees to in-
form the pricing and reimbursement decision-making within the 10 countries that
were included in the study (EU5, Sweden, Denmark, Mexico, Brazil and Argentina).
In countries such as Italy and Spain, ATC 3rd and 4th level classification is an
important determinant of reimbursement status of drugs for many chronic dis-
eases. In Germany and Denmark, price comparators for a new drug are sometimes
chosen from within the 4th level ATC classification. There are exceptions to this
when it comes to biologics, innovative products and orphan drugs. In Latin Amer-
ica, ATC classification plays a less influential role in pricing and reimbursement
and is mostly used in organisation of drug lists on the national formulary.
CONCLUSIONS: ATC classification plays a significant role in many countries in
Europe as a tool for supporting pricing and reimbursement decisions. Often over-
looked, ATC classification is an important consideration for pharmaceutical com-
panies at launch when determining the price of drugs.
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OBJECTIVES: In 1992, the French law introduced a legal framework for the provi-
sion of drugs without a French market authorization (MA) for compassionate use,
called temporary use authorization (ATU). This specific French program, aimed to
facilitate early access to innovative drugs, is suspected to be inflationary as ATUs
bypass public bodies in charge of health technology assessment and of pricing.
Moreover, the national health insurance fully reimburses ATU expenditures. The
objective of this work was to explore the economic status of previous ATUs before
and after they got a MA, in regards of their clinical benefits. METHODS: A retro-
spective descriptive analysis was performed on all ATUs that obtained a French MA
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